Haubner, S., Subklewe, M., & Sadelain, M. (2025). Honing CAR T cells to tackle acute myeloid leukemia. Blood, 145(11), 1113–1125. https://doi.org/10.1182/blood.2024024063

Gui, G., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., De Lima, M. J. G., Litzow, M. R., Kebriaei, P., Saber, W., Spellman, S. R., … Hourigan, C. S. (2024). Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02447-4

Hassan, N., Yi, H., Malik, B., Gaspard-Boulinc, L., Samaraweera, S. E., Casolari, D. A., Seneviratne, J., Balachandran, A., Chew, T., Duly, A., Carter, D. R., Cheung, B. B., Norris, M., Haber, M., Kavallaris, M., Marshall, G. M., Zhang, X. D., Liu, T., Wang, J., … Wang, J. Y. (2024). Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML. Blood, 144(1), 84–98. https://doi.org/10.1182/blood.2024024072

Mack, E. A., Dougher, M. C., Ginda, A. M., Cahill, C., Murter, M., Schell, K., Tanhehco, Y. C., Bhoj, V. G., Fesnak, A. D., Siegel, D. L., Kambayashi, T., Aqui, N. A., & O’Doherty, U. (2024). Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis. Blood, 143(11), 1049–1054. https://doi.org/10.1182/blood.2023021895

Paudel, B. B., Tan, S.-F., Fox, T. E., Ung, J., Golla, U., Shaw, J. J. P., Dunton, W., Lee, I., Fares, W. A., Patel, S., Sharma, A., Viny, A. D., Barth, B. M., Tallman, M. S., Cabot, M., Garrett-Bakelman, F. E., Levine, R. L., Kester, M., Feith, D. J., … Loughran, T. P. (2024). Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes. Blood Advances, 8(5), 1137–1142. https://doi.org/10.1182/bloodadvances.2023010535

Özdemir, C., Muratoğlu, B., Özel, B. N., Alpdündar-Bulut, E., Tonyalı, G., Ünal, Ş., & Uçkan-Çetinkaya, D. (2023). Multiparametric analysis of etoposide exposed mesenchymal stem cells and Fanconi anemia cells: implications in development of secondary myeloid malignancy. Clinical and Experimental Medicine, 23(8), 4511–4524. https://doi.org/10.1007/s10238-023-01087-0

Baruchel, A., Bourquin, J.-P., Crispino, J., Cuartero, S., Hasle, H., Hitzler, J., Klusmann, J.-H., Izraeli, S., Lane, A. A., Malinge, S., Rabin, K. R., Roberts, I., Ryeom, S., Tasian, S. K., & Wagenblast, E. (2023). Down syndrome and leukemia: from basic mechanisms to clinical advances. Haematologica, 108(10), 2570–2581. https://doi.org/10.3324/haematol.2023.283225

Pratz, K. W., Cherry, M., Altman, J. K., Cooper, B. W., Podoltsev, N. A., Cruz, J. C., Lin, T. L., Schiller, G. J., Jurcic, J. G., Asch, A., Wu, R., Hill, J. E., Gill, S. C., James, A. J., Rich, E. S., Hasabou, N., Perl, A. E., & Levis, M. J. (2023). Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. Journal of Clinical Oncology, 41(26), 4236–4246. https://doi.org/10.1200/jco.22.02721

Kintossou, A. K., Blanco-Lopez, J., Iguacel, I., Pisanu, S., Almeida, C. C. B., Steliarova-Foucher, E., Sierens, C., Gunter, M. J., Ladas, E. J., Barr, R. D., Van Herck, K., Kozlakidis, Z., & Huybrechts, I. (2023). Early Life Nutrition Factors and Risk of Acute Leukemia in Children: Systematic Review and Meta-Analysis. Nutrients, 15(17), 3775. https://doi.org/10.3390/nu15173775

Levy, B., Baughn, L. B., Akkari, Y., Chartrand, S., LaBarge, B., Claxton, D., Lennon, P. A., Cujar, C., Kolhe, R., Kroeger, K., Pitel, B., Sahajpal, N., Sathanoori, M., Vlad, G., Zhang, L., Fang, M., Kanagal-Shamanna, R., & Broach, J. R. (2023). Optical genome mapping in acute myeloid leukemia: a multicenter evaluation. Blood Advances, 7(7), 1297–1307. https://doi.org/10.1182/bloodadvances.2022007583

Szymczak, J. E., Getz, K. D., Madding, R., Shuster, S., Aftandilian, C., Arnold, S. D., Collier, A. B., Gramatges, M. M., Henry, M., Hijiya, N., Mian, A., Raetz, E., Fisher, B. T., & Aplenc, R. (2023). Child and family perceptions of satisfaction with neutropenia management in pediatric acute myeloid leukemia. Pediatric Blood & Cancer, 70(8). Portico. https://doi.org/10.1002/pbc.30420

de Botton, S., Fenaux, P., Yee, K., Récher, C., Wei, A. H., Montesinos, P., Taussig, D. C., Pigneux, A., Braun, T., Curti, A., Grove, C., Jonas, B. A., Khwaja, A., Legrand, O., Peterlin, P., Arnan, M., Blum, W., Cilloni, D., Hiwase, D. K., … Cortes, J. (2023). Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Advances, 7(13), 3117–3127. https://doi.org/10.1182/bloodadvances.2022009411

Unachukwu, U., Sonett, J., Woode, D., Shiomi, T., Chada, K., & D’Armiento, J. M. (2023). Tyrosine Kinase Inhibitors Diminish Renal Neoplasms in a Tuberous Sclerosis Model Via Induction of Apoptosis. Molecular Cancer Therapeutics, 22(7), 844–858. https://doi.org/10.1158/1535-7163.mct-22-0224

Williams, O., Hu, L., Huang, W., Patel, P., Bartom, E. T., Bei, L., Hjort, E., Hijiya, C., & Eklund, E. A. (2023). Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis but facilitates termination of emergency (stress) granulopoiesis. Journal of Biological Chemistry, 299(7), 104867. https://doi.org/10.1016/j.jbc.2023.104867

Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., Zeidner, J. F., Garcia-Manero, G., Jeyakumar, D., Komrokji, R., Lancet, J., Kantarjian, H. M., Gu, L., Zhang, Y., Tan, A., … Daver, N. G. (2023). Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of Clinical Oncology, 41(15), 2815–2826. https://doi.org/10.1200/jco.22.01794

de Botton, S., Cluzeau, T., Vigil, C., Cook, R. J., Rousselot, P., Rizzieri, D. A., Liesveld, J. L., Fenaux, P., Braun, T., Banos, A., Jurcic, J. G., Sekeres, M. A., Savona, M. R., Roboz, G. J., Bixby, D., Madigan, K., Volkert, A., Stephens, K., Kang-Fortner, Q., … Stein, E. M. (2023). Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML. Blood Advances, 7(9), 1858–1870. https://doi.org/10.1182/bloodadvances.2022008806

Blanco-Lopez, J., Iguacel, I., Pisanu, S., Almeida, C., Steliarova-Foucher, E., Sierens, C., Gunter, M., Ladas, E., Barr, R., Van Herck, K., & Huybrechts, I. (2023). Role of Maternal Diet in the Risk of Childhood Acute Leukemia: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 20(7), 5428. https://doi.org/10.3390/ijerph20075428

Boila, L. D., Ghosh, S., Bandyopadhyay, S. K., Jin, L., Murison, A., Zeng, A. G. X., Shaikh, W., Bhowmik, S., Muddineni, S. S. N. A., Biswas, M., Sinha, S., Chatterjee, S. S., Mbong, N., Gan, O. I., Bose, A., Chakraborty, S., Arruda, A., Kennedy, J. A., Mitchell, A., … Sengupta, A. (2023). KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition. Leukemia, 37(4), 751–764. https://doi.org/10.1038/s41375-023-01833-z

Sembill, S., Ampatzidou, M., Chaudhury, S., Dworzak, M., Kalwak, K., Karow, A., Kiani, A., Krumbholz, M., Luesink, M., Naumann-Bartsch, N., De Moerloose, B., Osborn, M., Schultz, K. R., Sedlacek, P., Giona, F., Zwaan, C. M., Shimada, H., Versluijs, B., Millot, F., … Metzler, M. (2023). Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations. Leukemia, 37(3), 505–517. https://doi.org/10.1038/s41375-023-01822-2

DiNardo, C. D., Hochhaus, A., Frattini, M. G., Yee, K., Zander, T., Krämer, A., Chen, X., Ji, Y., Parikh, N. S., Choi, J., & Wei, A. H. (2022). A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. Journal of Cancer Research and Clinical Oncology, 149(3), 1145–1158. https://doi.org/10.1007/s00432-022-03983-6

Burke, A., Borot, F., Du, X., Churchill, M., Ding, J., Grass, A. M., DeSouza, P., Ali, A. M., & Mukherjee, S. (2022). A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia. Oncogene, 42(1), 26–34. https://doi.org/10.1038/s41388-022-02532-2

Xu, J., Song, F., Lyu, H., Kobayashi, M., Zhang, B., Zhao, Z., Hou, Y., Wang, X., Luan, Y., Jia, B., Stasiak, L., Wong, J. H., Wang, Q., Jin, Q., Jin, Q., Fu, Y., Yang, H., Hardison, R. C., Dovat, S., … Yue, F. (2022). Subtype-specific 3D genome alteration in acute myeloid leukaemia. Nature, 611(7935), 387–398. https://doi.org/10.1038/s41586-022-05365-x

Prebet, T., Goldberg, A. D., Jurcic, J. G., Khaled, S., Dail, M., Feng, Y., Green, C., Li, C., Ma, C., Medeiros, B. C., Yan, M., & Grunwald, M. R. (2022). A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. Leukemia & Lymphoma, 63(9), 2180–2188. https://doi.org/10.1080/10428194.2022.2057484

Meyer, A. E., Stelloh, C., Pulakanti, K., Burns, R., Fisher, J. B., Heimbruch, K. E., Tarima, S., Furumo, Q., Brennan, J., Zheng, Y., Viny, A. D., Vassiliou, G. S., & Rao, S. (2022). Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML. Leukemia, 36(8), 2032–2041. https://doi.org/10.1038/s41375-022-01632-y

Rosenblat, T. L., McDevitt, M. R., Carrasquillo, J. A., Pandit-Taskar, N., Frattini, M. G., Maslak, P. G., Park, J. H., Douer, D., Cicic, D., Larson, S. M., Scheinberg, D. A., & Jurcic, J. G. (2022). Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. Clinical Cancer Research, 28(10), 2030–2037. https://doi.org/10.1158/1078-0432.ccr-21-3712

Galán-Díez, M., Borot, F., Ali, A. M., Zhao, J., Gil-Iturbe, E., Shan, X., Luo, N., Liu, Y., Huang, X.-P., Bisikirska, B., Labella, R., Kurland, I., Roth, B. L., Quick, M., Mukherjee, S., Rabadán, R., Carroll, M., Raza, A., & Kousteni, S. (2022). Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid Leukemia. Cancer Discovery, 12(4), 1106–1127. https://doi.org/10.1158/2159-8290.cd-21-0692